Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 3/20 | 0.63 |
| ▸ | JAK2 | O60674 | 2/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 15/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491056 | 1.00 | IKBKB (0.63) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL1148020 | 0.91 | IKBKB (0.62) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL490653 | 0.86 | IKBKB (0.68) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL490930 | 0.85 | CHEK1 (0.69) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL490632 | 0.85 | CHEK1 (0.69) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL490596 | 0.84 | IKBKB (0.59) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL490749 | 0.83 | CHEK1 (0.60) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL491060 | 0.83 | CHEK1 (0.60) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL490619 | 0.82 | CHEK1 (0.70) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL491021 | 0.82 | CHEK1 (0.70) | IKBKBJAK2JAK3CHEK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086956-B1 | INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2011-09-14 | — | — | EP | claimed |
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| EP-2086956-B1 | INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2011-09-14 | — | — | EP | disclosed |
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | IKBKB, IKBKE, CHUK | IKBKB 1/4885JAK2 1292/4885JAK3 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.